BioNTech vs Gilboa Therapeutics
BioNTech vs Gilboa Therapeutics, compared side by side on 14 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: BioNTech is on 66/100 and Gilboa Therapeutics on 43/100.
Where each one leads
BioNTech
- our overall score: 66/100 against 43/100
- agent readiness: 40/100 against 22/100
- domain rating: 74/100 against 4/100
- headcount: 5,128 against 2
- LinkedIn following: 295,812 against 956
Gilboa Therapeutics
Leads on none of the measures we hold for both companies.
At a glance
| Measure | BioNTech | Gilboa Therapeutics |
|---|---|---|
| What it is | Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases. | Preclinical biopharma developing next-gen cancer immunotherapies using proprietary SolidT technology. |
| Category | Biotechnology, Drug Discovery, Oncology, Immunotherapy | Biopharmaceuticals, Immunotherapy, Cancer Treatment, Biotechnology |
| Sells toBusiness model | B2B | B2G |
| Offering | Biotechnology | Hardware |
| Founded | 2008 | 2017 |
| Headquarters | Mainz, Germany | Tel Aviv, Israel |
| Status | Active | Inactive |
Size, funding and growth
| Measure | BioNTech | Gilboa Therapeutics |
|---|---|---|
| Employees | 5,128 | 2 |
| Headcount growthLast 12 months | Not published | -49.5% |
| Total funding | $975M | Not published |
| Latest round | Loan | Not published |
| LinkedIn followers | 295,812 | 956 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | BioNTech | Gilboa Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 66/100 | 43/100 |
| Traction | 60/100 | 11/100 |
| Team | 70/100 | Not published |
| Search visibility | 35/100 | 54/100 |
| Quality | 78/100 | Not published |
| Agent readinessHow well an AI agent can read and act on the site | D (40/100) | F (22/100) |
| Domain ratingLink authority, 0-100 | 74/100 | 4/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | BioNTech | Gilboa Therapeutics |
|---|---|---|
| Hosting | Azure | Not detected |
| Analytics | Google Tag Manager | Not detected |
BioNTech vs Gilboa Therapeutics: common questions
Which is better, BioNTech or Gilboa Therapeutics?
On our 0-100 score BioNTech rates higher (66/100 against 43/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 14 data points above: read the rows that match what you are buying for.
How do BioNTech and Gilboa Therapeutics compare on the numbers?
BioNTech leads on our overall score (66/100 against 43/100), agent readiness (40/100 against 22/100), domain rating (74/100 against 4/100), headcount (5,128 against 2), LinkedIn following (295,812 against 956).
Read the full BioNTech review and pricing or the Gilboa Therapeutics review and pricing. You can also browse other BioNTech alternatives we track.